Historique
Article de Périodique
Designer drugs 2015: Assessment and management (2015)
Auteur(s) :
WEAVER, M. ;
HOPPER, J. ;
GUNDERSON, E. W.
Année
2015
Page(s) :
9 p.
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
73
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
DROGUES DE SYNTHESE
;
CATHINONES
;
MEPHEDRONE
;
CANNABINOIDES
;
HALLUCINOGENES
;
TOXICITE
;
PHENOMENE EMERGENT
;
PHARMACOLOGIE
;
EFFET SECONDAIRE
;
SYMPTOME
Résumé :
Recent designer drugs, also known as "legal highs," include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as "bath salts"); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.
Affiliation :
The University of Texas Health Science Center at Houston, Houston, TX, USA